Company Akari Therapeutics, Plc

Equities

AKTX

US00972G2075

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Delayed Nasdaq Other stock markets 11:45:52 2024-04-29 am EDT			5-day change	1st Jan Change
1.225 ^USD	+3.38%		+3.81%	-60.74%

05:27pm	European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading	MT
Apr. 24	European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	MT

Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). It is conducting a clinical trial of subcutaneous nomacopan for the treatment of HSCT-TMA in pediatrics. The United States Food and Drug Administration (FDA) has granted Rare Pediatric Disease, Orphan Drug, and Fast Track designations to nomacopan for the treatment of pediatric HSCT-TMA. It is also investigating long-acting PASylated-nomacopan (PAS-nomacopan) for treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) in preclinical studies.

Number of employees: 11

Managers	Title	Age	Since
Jacques Suzanne CEO	Chief Executive Officer	53	22-03-27
Raymond Prudo-Chlebosz FOU	Founder	79	15-08-31
Wendy DiCicco DFI	Director of Finance/CFO	56	23-07-18
Miles Nunn CTO	Chief Tech/Sci/R&D Officer	-	15-08-31
John Neylan CTO	Chief Tech/Sci/R&D Officer	70	22-11-07
Melissa Bradford-Klug COO	Chief Operating Officer	-	22-06-30

Members of the board	Title	Age	Since
Donald Williams BRD	Director/Board Member	65	16-05-31
Raymond Prudo-Chlebosz FOU	Founder	79	15-08-31
Mohamed Wa’el Ahmed Hashad BRD	Director/Board Member	61	23-07-04
Samir R. Patel BRD	Director/Board Member	55	Nov. 28
Michael Grissinger BRD	Director/Board Member	70	18-01-22
Jacques Suzanne CEO	Chief Executive Officer	53	22-03-27

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	13,234,315,298	3,808,858,604 ( 28.78 %)	0	28.78 %

Name	Equities	%	Valuation
Sabby Management LLC 2.484 %	164,026	2.484 %	305 908 $
Omnia Family Wealth LLC 1.327 %	87,628	1.327 %	163 426 $
Cerity Partners LLC 0.3581 %	23,643	0.3581 %	44 094 $
Renaissance Technologies LLC 0.1555 %	10,269	0.1555 %	19 152 $
BG Fund Management Luxembourg SA 0.0926 %	6,114	0.0926 %	11 403 $
Bank of America, NA (Charlotte, North Carolina) 0.002272 %	150	0.002272 %	280 $
Truvestments Capital LLC 0.000757 %	50	0.000757 %	93 $
Morgan Stanley Smith Barney LLC 0.000121 %	8	0.000121 %	15 $
Tower Research Capital LLC 0.000106 %	7	0.000106 %	13 $
Cornerstone Planning Group LLC 0.000076 %	5	0.000076 %	9 $

Name	Equities	%	Valuation
Raymond Prudo-Chlebosz 23.06 %	2,331,580,600	23.06 %	6 M $
Pranabio Investments LLC 20.62 %	2,085,237,500	20.62 %	5 M $
RPC Pharma Ltd. 8.302 %	839,476,200	8.302 %	2 M $
Samir R. Patel 5.561 %	562,329,900	5.561 %	1 M $
Jacques Suzanne 5.325 %	538,457,900	5.325 %	1 M $
Stuart Ungar 0.1978 %	20,000,020	0.1978 %	50 000 $
James Hill 0.1978 %	20,000,000	0.1978 %	50 000 $
David Byrne 0.1978 %	20,000,000	0.1978 %	50 000 $
Michael Grissinger 0.1978 %	20,000,000	0.1978 %	50 000 $
Donald Williams 0.1978 %	20,000,000	0.1978 %	50 000 $

Akari Therapeutics Plc

22 Boston Wharf Road 7th Floor

02210, Boston

+44 20 8004 0270

http://www.akaritx.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
AKARI THERAPEUTICS, PLC	-59.29%	9.39M
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	103B
REGENERON PHARMACEUTICALS, INC.	+1.82%	95.28B
ARGENX SE	+1.46%	22.15B
BIONTECH SE	-15.45%	21.02B
GENMAB A/S	-8.58%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-13.43%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+4.61%	13.68B
SAREPTA THERAPEUTICS, INC.	+35.27%	12.17B

Bio Therapeutic Drugs